News
Cortado Ventures Doubleshot Newsletter: October 2022
Bottom Line Up Front...
Cortado Ventures Doubleshot Newsletter: September 2022
Bottom Line Up Front...
Moat Biotechnology Forms To Develop Novel Mucosal Vaccines for Covid-19 and Beyond: Announces Initial Funding Round and Promising Phase I trial results for Intranasal Covid-19 Vaccine
Moat Biotechnology...
Cortado Ventures Doubleshot Newsletter: August 2022
Cortado Ventures Starts Second Close at $40M for Fund II and more…
Cortado Ventures Starting Second Close at $40M for Fund II
The Oklahoma City-based firm reaches halfway mark of Fund II, bringing total assets under management to $70MM.
Cortado Ventures Doubleshot Newsletter: July 2022
Ecosystem highlights...
Cortado featured in Wall Street Journal Pro Newsletter
Cortado Ventures Makes Headway Toward Second Early-Stage Fund
Cortado Ventures Doubleshot Newsletter: June 2022
The June issue of Cortado Venture’s Doubleshot newsletter features the latest updates on investments, advancements and key stories of interest in the entrepreneurial ecosystem.
Industry Classfication: Solved
NAICS codes are vital...
The Advantages of Venture Capital in the Midcontinent
With a record $128...
Cortado Ventures Doubleshot Newsletter: May 2022
Introducing Doubleshot...
Cortado Ventures Featured on OETA’s Oklahoma News Report
In April, Cortado Ventures was featured on OETA, Oklahoma’s PBS affiliate, focusing on the firm’s efforts to raise $80M for our second fund and invest in more high-growth tech startups in Oklahoma and the Midcontinent region.
Cortado Ventures Reaches First Close of Fund II
First $20M committed in under 6 weeks
Cortado Ventures Monthly Update: April
Cortado Ventures...
Cortado Co-Leads Recuro Health Convertible Note
Recuro Health Announces Convertible Note Financing Co-Led by ARCH Venture Partners & Cortado Ventures: Funds Rapid Expansion of Digital Health Platform.
CORTADO VENTURES
